Policy

Biosimilars Policy Roundup for October 2022—Podcast Edition

November 6th 2022

By Skylar Jeremias

On this episode of Not So Different, we recap some of the biosimilar policy news from the around the world during October, including the implementation of a biosimilars switching policy, the European Union declaration of biosimilars as interchangeable, and the reauthorization of the Biosimilars User Fee Act.

Biosimilars Policy Roundup: October 2022

October 31st 2022

By Skylar Jeremias

Article

October ushered in a number of policy updates, including the implementation of a biosimilars switching policy, the European Union declaration of biosimilars as interchangeable, and the reauthorization of the Biosimilars User Fee Act.

Dr Ryan Haumschild: What Health Systems Can Learn From Emory Healthcare's Biosimilar Strategy

October 30th 2022

By Skylar Jeremias

Video

Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, offers advice to health systems on how they can incorporate some of Emory Healthcare's strategies to promote biosimilar uptake.

Saskatchewan Becomes Sixth Canadian Province to Implement a Biosimilar Switching Policy

October 20th 2022

By Skylar Jeremias

Article

Saskatchewan joined 5 provinces and 1 territory in implementing a biosimilar switching policy, allowing for reference products to be switched out for biosimilars and lowering drug costs for the province’s public health plan.

Biden Authorizes Update to the Biosimilar User Fee Act Through 2027

October 20th 2022

By Skylar Jeremias

Article

After months of pressure and calls for action, President Biden reauthorized the Biosimilar User Fee Act, which will allow the FDA to assess and collect fees for biosimilars for the next 5 years.

Amgen Report: Biosimilars Have Saved $21 Billion in 6 Years

October 19th 2022

By Skylar Jeremias

Article

Amgen’s ninth edition of its Biosimilar Trends Report explores the evolution of the US biosimilar industry, including current trends, predictions for the next few years, advice for stakeholders going forward, and insight into how reimbursement and other policies could develop.

Order of Operations: Managing Biosimilars While Maintaining Operational Efficiency

October 16th 2022

By Skylar Jeremias

Podcast

In this podcast episode, Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, discussed the stresses that practices and clinics face when trying to manage biosimilars as well as some policy considerations that administrators should keep in mind as more biosimilars enter the market and are added to formularies.

Advocacy Organization Calls for Ontario to Switch Patients to Biosimilars

October 11th 2022

By Skylar Jeremias

Article

Biosimilars Canada, a national association representing the Canadian biosimilar industry, held a press conference calling on Ontario, the province containing the nation’s capital, to institute a biosimilars switching policy.

Dr Ryan Haumschild Compares Viewpoints on Biosimilar Value Between Stakeholders

October 4th 2022

By Skylar Jeremias

Video

Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, explains how stakeholders may view the economic value of biosimilars differently based on their goals and his predictions for how biosimilar utilization will develop in the future.

Biosimilar Medicare Part B Payment Boost Begins

October 3rd 2022

By Allison Inserro

Article

Under the Inflation Reduction Act, there is a 5-year temporary increase in the add-on payment for qualifying biosimilars whose average sales price (ASP) is not more than the price of the reference product.